EOLS vs PCRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 03, 2026

EOLS

44.0
AI Score
VS
PCRX Wins

PCRX

54.7
AI Score

Investment Advisor Scores

EOLS

44score
Recommendation
HOLD

PCRX

55score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric EOLS PCRX Winner
Revenue 73.14M 177.38M PCRX
Net Income -10.67M 2.92M PCRX
Net Margin -14.6% 1.6% PCRX
Operating Income -6.85M 6.90M PCRX
ROE 37.1% 0.4% EOLS
ROA -4.8% 0.2% PCRX
Total Assets 220.65M 1.21B PCRX
Cash 49.79M 144.31M PCRX
Debt/Equity -5.43 0.56 EOLS
Current Ratio 2.04 4.73 PCRX
Free Cash Flow -10.37M 22.96M PCRX

Relative Price Performance (Last 90 Days)

EOLS 1M: -12.3% · 3M: +13.5% PCRX 1M: +6.0% · 3M: +10.1%

Current Technical Phase

EOLS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 46.1 · Price: $6.05

PCRX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (3.3% over 20 days), RSI 64

RSI (14): 64.0 · Price: $26.92

Fundamentals Snapshot

Metric EOLS PCRX
Market Cap
Forward P/E 25.2 7.4
Trailing P/E 203.2
Revenue (TTM)
Revenue Growth 0.1% 0.1%
Gross Margin 0.7% 0.8%
Operating Margin -0.1% 0.0%
EPS -0.66 0.13
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, PCRX is currently the stronger investment candidate, winning 9 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.